Logo image of ZYXI

ZYNEX INC (ZYXI) Stock Fundamental Analysis

NASDAQ:ZYXI - Nasdaq - US98986M1036 - Common Stock - Currency: USD

2.58  +0.05 (+1.98%)

After market: 2.6 +0.02 (+0.78%)

Fundamental Rating

3

Taking everything into account, ZYXI scores 3 out of 10 in our fundamental rating. ZYXI was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of ZYXI get a neutral evaluation. Nothing too spectacular is happening here. ZYXI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ZYXI had negative earnings in the past year.
In the past year ZYXI had a positive cash flow from operations.
Each year in the past 5 years ZYXI has been profitable.
In the past 5 years ZYXI always reported a positive cash flow from operatings.
ZYXI Yearly Net Income VS EBIT VS OCF VS FCFZYXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

1.2 Ratios

ZYXI has a Return On Assets of -7.01%. This is in the better half of the industry: ZYXI outperforms 64.71% of its industry peers.
The Return On Equity of ZYXI (-35.68%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.01%
ROE -35.68%
ROIC N/A
ROA(3y)8.05%
ROA(5y)9.92%
ROE(3y)18.36%
ROE(5y)18.84%
ROIC(3y)N/A
ROIC(5y)N/A
ZYXI Yearly ROA, ROE, ROICZYXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

In the last couple of years the Profit Margin of ZYXI has declined.
In the last couple of years the Operating Margin of ZYXI has declined.
ZYXI has a better Gross Margin (77.84%) than 91.98% of its industry peers.
In the last couple of years the Gross Margin of ZYXI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ZYXI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.84%
OM growth 3Y-43.42%
OM growth 5Y-33.75%
PM growth 3Y-50.87%
PM growth 5Y-40.5%
GM growth 3Y0.14%
GM growth 5Y-0.29%
ZYXI Yearly Profit, Operating, Gross MarginsZYXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

ZYXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZYXI has been reduced compared to 1 year ago.
Compared to 5 years ago, ZYXI has less shares outstanding
ZYXI has a worse debt/assets ratio than last year.
ZYXI Yearly Shares OutstandingZYXI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ZYXI Yearly Total Debt VS Total AssetsZYXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ZYXI has an Altman-Z score of 2.65. This is not the best score and indicates that ZYXI is in the grey zone with still only limited risk for bankruptcy at the moment.
ZYXI has a Altman-Z score of 2.65. This is in the better half of the industry: ZYXI outperforms 63.64% of its industry peers.
A Debt/Equity ratio of 2.87 is on the high side and indicates that ZYXI has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.87, ZYXI is doing worse than 88.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF N/A
Altman-Z 2.65
ROIC/WACCN/A
WACC6.9%
ZYXI Yearly LT Debt VS Equity VS FCFZYXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

ZYXI has a Current Ratio of 3.46. This indicates that ZYXI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ZYXI (3.46) is better than 62.03% of its industry peers.
A Quick Ratio of 2.63 indicates that ZYXI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.63, ZYXI is in line with its industry, outperforming 59.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 2.63
ZYXI Yearly Current Assets VS Current LiabilitesZYXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ZYXI have decreased strongly by -160.00% in the last year.
ZYXI shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.77% yearly.
Looking at the last year, ZYXI shows a decrease in Revenue. The Revenue has decreased by -8.63% in the last year.
Measured over the past years, ZYXI shows a very strong growth in Revenue. The Revenue has been growing by 33.42% on average per year.
EPS 1Y (TTM)-160%
EPS 3Y-41.04%
EPS 5Y-18.77%
EPS Q2Q%-109766.67%
Revenue 1Y (TTM)-8.63%
Revenue growth 3Y13.86%
Revenue growth 5Y33.42%
Sales Q2Q%-42.88%

3.2 Future

The Earnings Per Share is expected to decrease by -4.52% on average over the next years.
ZYXI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.87% yearly.
EPS Next Y-987.77%
EPS Next 2Y-148.86%
EPS Next 3Y-51.61%
EPS Next 5Y-4.52%
Revenue Next Year-41.75%
Revenue Next 2Y-16.55%
Revenue Next 3Y-3.5%
Revenue Next 5Y4.87%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ZYXI Yearly Revenue VS EstimatesZYXI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ZYXI Yearly EPS VS EstimatesZYXI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZYXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYXI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYXI Price Earnings VS Forward Price EarningsZYXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYXI Per share dataZYXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

ZYXI's earnings are expected to decrease with -51.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-148.86%
EPS Next 3Y-51.61%

More info and screens

0

5. Dividend

5.1 Amount

ZYXI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYNEX INC

NASDAQ:ZYXI (7/25/2025, 8:00:02 PM)

After market: 2.6 +0.02 (+0.78%)

2.58

+0.05 (+1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners22.41%
Inst Owner Change3.5%
Ins Owners48.39%
Ins Owner Change-6.36%
Market Cap78.02M
Analysts77.78
Price Target6.12 (137.21%)
Short Float %22.93%
Short Ratio15.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-65.69%
DP-0.08%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.3%
Min EPS beat(2)-121.79%
Max EPS beat(2)-34.8%
EPS beat(4)1
Avg EPS beat(4)-46.09%
Min EPS beat(4)-121.79%
Max EPS beat(4)21.1%
EPS beat(8)4
Avg EPS beat(8)-20.26%
EPS beat(12)8
Avg EPS beat(12)4.13%
EPS beat(16)11
Avg EPS beat(16)4.96%
Revenue beat(2)0
Avg Revenue beat(2)-15.74%
Min Revenue beat(2)-15.99%
Max Revenue beat(2)-15.48%
Revenue beat(4)0
Avg Revenue beat(4)-10.3%
Min Revenue beat(4)-15.99%
Max Revenue beat(4)-3.62%
Revenue beat(8)0
Avg Revenue beat(8)-7.97%
Revenue beat(12)1
Avg Revenue beat(12)-5.46%
Revenue beat(16)1
Avg Revenue beat(16)-4.88%
PT rev (1m)0%
PT rev (3m)-41.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-63.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-389.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.45
P/FCF N/A
P/OCF 520.13
P/B 3.76
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFY0.19%
SpS5.7
BVpS0.69
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.01%
ROE -35.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.84%
FCFM N/A
ROA(3y)8.05%
ROA(5y)9.92%
ROE(3y)18.36%
ROE(5y)18.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)12.93%
ROCE(5y)15.14%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-43.42%
OM growth 5Y-33.75%
PM growth 3Y-50.87%
PM growth 5Y-40.5%
GM growth 3Y0.14%
GM growth 5Y-0.29%
F-Score4
Asset Turnover1.63
Health
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.41%
Cap/Sales 0.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 2.63
Altman-Z 2.65
F-Score4
WACC6.9%
ROIC/WACCN/A
Cap/Depr(3y)18.03%
Cap/Depr(5y)28.76%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.58%
Profit Quality(3y)218.02%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160%
EPS 3Y-41.04%
EPS 5Y-18.77%
EPS Q2Q%-109766.67%
EPS Next Y-987.77%
EPS Next 2Y-148.86%
EPS Next 3Y-51.61%
EPS Next 5Y-4.52%
Revenue 1Y (TTM)-8.63%
Revenue growth 3Y13.86%
Revenue growth 5Y33.42%
Sales Q2Q%-42.88%
Revenue Next Year-41.75%
Revenue Next 2Y-16.55%
Revenue Next 3Y-3.5%
Revenue Next 5Y4.87%
EBIT growth 1Y-169.24%
EBIT growth 3Y-35.57%
EBIT growth 5Y-11.61%
EBIT Next Year-118.41%
EBIT Next 3Y-35.35%
EBIT Next 5Y14.23%
FCF growth 1Y-103.31%
FCF growth 3Y24.19%
FCF growth 5Y14.61%
OCF growth 1Y-98.92%
OCF growth 3Y22.32%
OCF growth 5Y15.09%